Bird & Bird successfully represents Gilead in Hungarian compulsory license matter

Contacts

balint halasz module
Bálint Halász

Partner
Hungary

As a partner and co-Head of Country of the Budapest office, I am heading the IP, Data Protection and TMT teams. <BR/><BR/>I advise on intellectual property, information technology and privacy and data protection matters for our national and international clients from various sectors including electronics, pharmaceuticals, retail and IT.

Bird & Bird’s Intellectual Property team has won an action before the Hungarian Constitutional Court for their client Gilead in its three years running dispute regarding a public health related compulsory license granted in Hungary.

In December 2020, the Hungarian Intellectual Property Office (HIPO) granted compulsory licenses for three patents concerning remdesivir, an active substance developed by Gilead - a pioneer and leader in antiviral drug development - without the patentee being heard. Gilead filed appeals but lower courts and the Hungarian supreme court believed that grant has happened in lawful proceedings. In September 2022, the patentee sought final recourse by filing complaints to the Hungarian Constitutional Court.

In its decision dated 10 October 2023 the Constitutional Court found that both the administrative law proceedings at the HIPO and the appeal stages at court violated the Fundamental law of Hungary. The Constitutional Court annulled all the decisions made in the case.

Gilead was represented by the following Bird & Bird lawyers: Partner Bálint Halász and Counsel Bettina Kövecses.

Partner Bálint Halász and Counsel Bettina Kövecses commented “The provisions on public health related compulsory licensing were introduced to Hungarian law in May 2020. This case is truly a landmark case as this was the first case of this kind. The ruling of the Constitutional Court clarified that a compulsory license can only be granted if a patentee was able to exercise their client rights, including the right to be heard and have access to files. Furthermore the patentee’s right to appeal cannot become a mere formality and the principle of equality of arms always must be ensured.

News & Deals

More News & Deals

News

Bird & Bird partners with Aalto University to support spinoff companies

Nov 06 2024

Read More

Deal

Bird & Bird advises Vanagon Ventures on pre-seed investment in ExoMatter

Nov 05 2024

Read More

Deal

Bird & Bird advises Edita Group on Divestment of Edita Prima

Nov 04 2024

Read More

Deal

Bird & Bird advised Sydev on its partnership with Turenne Emergence

Oct 30 2024

Read More

Deal

Bird & Bird advise Emerge Education on its participation in Mendo's fundraising round

Oct 30 2024

Read More

Deal

Bird & Bird advises Mothercare Global Brand Limited on sale of shares

Oct 30 2024

Read More

Related capabilities